

7 April 2021

## ASX ANNOUNCEMENT

### Option Exercise and Preliminary Q3 FY'21 Cashflow Results

**Brisbane, Australia** – ImpediMed Limited (ASX:IPD), a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health, today announced the results of the final Entitlement Offer Option Exercise and Preliminary Cashflow Results for the period ended 31 March 2021 (Q3 FY'21).

#### Option Exercise for March 2021 Option exercise date

- **\$8.8 million in Option exercise funds were received for the Q3 FY'21 exercise period.**
- **In total, \$17.9 million out of a possible \$18.2 million in Option exercise funds were received over the four exercise periods, equating to a 98% exercise rate.**
- The Company will exercise the March 2021 options today, within the 5 business days allowed by the April 2020 Entitlement issue prospectus. As a result, 234,287,184 new shares will be issued for the March 2021 option exercise period.
- The new shares will be allocated back to the Shareholder's SRN if they utilised the BPay payment facility. Shareholders will need to contact their Sponsoring Broker if they wish to have the new shares transferred to their existing HIN.
- All remaining Entitlement Offer Options have now lapsed.

#### Preliminary Cashflow Results for the Quarter Ending 31 March 2021

- **Net operating cash outflow is expected to be below \$3.5 million for Q3 FY'21**, better than the forecasted \$4.0 million net operating cash outflow announced to the market on 28 January 2021.
- **The cash balance as at 31 March 2021 was \$23.9 million**, including the March Option exercise funds.

#### Appendix 4C – Quarterly Cash Flow Report for the period ended 31 March 2020

- The Q3 FY'21 Appendix 4C Quarterly Cashflow Results will be released on Wednesday, 28 April 2021.
- Conference call details will be released closer to the date.
- The Company will cover the following:
  - Strong quarterly performance in difficult conditions, amidst headwinds from the record COVID-19 cases in the US during the quarter and the weather event in Texas.
  - Updates on the PREVENT Trial, including the PREVENT manuscript that was submitted in February 2021, as previously forecast.
  - Updates on Reimbursement, Heart Failure and Renal Failure.

**Approved for release by the Managing Director and CEO, Mr Richard Carreon.**

## Contact Details

### Investor Relations Contact:

Mike Bassett, ImpediMed  
T: +61 407 431 432  
E: [mbassett@impedimed.com](mailto:mbassett@impedimed.com)

### Media Contact:

Kyahn Williamson, WE Communications  
T: +61 3 8866 1200  
E: [kwilliamson@we-worldwide.com](mailto:kwilliamson@we-worldwide.com)

### About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition sold in select markets globally.

For more information, visit [www.impedimed.com](http://www.impedimed.com).

### Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.